Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Long-Term Deferred Tax (2009 - 2025)

Grifols' (GIFLF) quarterly Long-Term Deferred Tax came in at $484.2 million in Q4 2025, up 32.5% on a YoY basis from $365.5 million in Q4 2024, and up 32.5% quarter-over-quarter from $365.5 million in Q4 2024.

Analysis

Grifols (GIFLF) Long-Term Deferred Tax (2009 - 2025) Analysis & Trends

Grifols (GIFLF) has reported Long-Term Deferred Tax for 17 consecutive years, with $484.2 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Deferred Tax rose 32.5% year-over-year to $484.2 million; the trailing twelve-month figure through Dec 2025 stood at $484.2 million (up 32.5% YoY), and the FY2025 full-year result was $470.0 million, up 28.61% from the prior year.
  • Long-Term Deferred Tax improved to $484.2 million in Q4 2025 per GIFLF's latest filing, from $365.5 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $323.1 billion in Q4 2023 and bottomed at $174.5 million in Q4 2021.
  • Historically, Long-Term Deferred Tax has averaged $100.5 billion across 5 years, with a median of $484.2 million in 2025.
  • The sharpest annual moves came in 2022 and 2024: Long-Term Deferred Tax jumped 102193.4% in 2022, then tumbled 99.89% in 2024.
  • Over 5 years, Long-Term Deferred Tax stood at $174.5 million in 2021, then surged by 102193.4% to $178.5 billion in 2022, then soared by 81.06% to $323.1 billion in 2023, then sank by 99.89% to $365.5 million in 2024, then soared by 32.5% to $484.2 million in 2025.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $484.2 million, $365.5 million, and $323.1 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 484.24 Mn
Dec 31, 2024 365.46 Mn
Dec 31, 2023 323.14 Bn
Dec 31, 2022 178.46 Bn
Dec 31, 2021 174.46 Mn
Dec 31, 2020 178.75 Mn
Dec 31, 2019 136.17 Mn
Dec 31, 2018 128.45 Mn
Jun 30, 2018 80.03 Mn
Dec 31, 2017 77.90 Mn
Jun 30, 2017 85.92 Mn
Dec 31, 2016 72.58 Mn
Sep 30, 2016 76.38 Mn
Jun 30, 2016 74.38 Mn
Dec 31, 2015 73.21 Mn
Sep 30, 2015 74.84 Mn
Jun 30, 2015 79,576.80
Mar 31, 2015 92.69 Mn
Dec 31, 2014 103.04 Mn
Sep 30, 2014 149.28 Mn